<DOC>
	<DOC>NCT02204293</DOC>
	<brief_summary>Interleukin-1 antagonists such as canakinumab have been used for the treatment of AOSD and have had a marked influence on the activity of the disease, including joint mobility. Results from controlled clinical studies are not, however, currently available.</brief_summary>
	<brief_title>Canakinumab for Treatment of Adult Onset Still's Disease</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Still's Disease, Adult-Onset</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Written and signed consent from the patient to participate in the study 2. Men and women aged ≥ 18 years and ≤ 75 years 3. Fulfilment of AOSD classification criteria (according to Yamaguchi et al, J. Rheumatology, 1992) 4. Disease activity based on DAS28 of ≥3.2 at screening 5. At least 4 painful and 4 swollen joints at screening and baseline (of the 28 joints according to DAS28) 6. If undergoing treatment with NSAIDs, stable dose for at least 4 weeks prior to randomisation 7. If undergoing treatment with glucocorticoids, stable dose of ≤10 mg/day (prednisolone or equivalent) for at least 4 weeks prior to randomisation 8. If undergoing treatment with conventional DMARD, stable dose for at least 3 months prior to randomisation 9. Normalisation period for biological DMARDS (Anakinra 1 week, Etanercept 1 month, Adalimumab and Certolizumab 2 months, Infliximab, Golimumab, Abatacept and Tociluzumab 3 months, Rituximab 9 months, canakinumab 6 months) prior to randomisation 10. In patients of reproductive age, use of an effective method of contraception as well as negative pregnancy test prior to the study commencing. 1. Previous treatment with the study drug with repeated administration of canakinumab 2. Intraarticular or intravenous administration of glucocorticoids within 4 weeks prior to the baseline or use of narcotic analgesics except for analgesics permitted within the framework of the investigation (Codeine and Tramadol) 3. Presence of another, serious chronicinflammatory disease 4. Positive Hepatitis B antigen (HBsAg), Hepatitis C antibodies and/or HIV antibodies. 5. Presence of a relevant, active infection or other diseases, which entail a tendency towards infection. 6. Positive screening for latent tuberculosis, in accordance with usual local practice 7. Raised liver count (raised bilirubin; ALT or AST ≥3fold the normal range) 8. Serumcreatinine concentration &gt;1.5 mg/dl 9. Inadequate haematological findings (Hb ≤ 10 g/dl, neutrophils ≤2,500/µl and thrombocytes ≤100,000/µl) 10. Simultaneous participation in any other interventional clinical study within the last 30 days preceding the commencement of the study 11. History of neoplasia with the exception of a curatively treated nonmelanoma skin tumour or carcinoma of the cervix treated in situ without any indication of recurrence within the last 10 years 12. Relevant cardiac or pulmonary disorders 13. Severe intercurrent neurological or psychiatric disorders 14. Macrophage activation syndrome (MAS) as part of previous treatment with IL1 blockade (e.g. Anakinra, Rilonacept) 15. Vaccination with a live vaccine within 3 months before the baseline 16. Alcohol or drug abuse in the past 12 months 17. ≥400 ml donation of blood or loss up to 8 weeks before the baseline 18. Pregnancy or breastfeeding 19. Commitment of the patient to an institution at the direction of an authority or court</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adult-Onset Still´s Disease</keyword>
	<keyword>Canakinumab</keyword>
	<keyword>Joint involvement</keyword>
	<keyword>AOSD</keyword>
</DOC>